October 30, 2001 — SALT LAKE CITY, UT — Cyclopss Corporation has entered into a system development contract with the New Jersey based pharmaceutical company PHARMACIA. The contract calls for Cyclopss to utilize a proprietary ozone technology to develop a new process for decontamination, disinfection and aseptic maintenance in the manufacturing and packaging of certain PHARMACIA’S products.

The contract will process through three phases; over the next few months; (1) An initial proof of concept, which is underway; (2) A Pathfinder test System, (3) A fully functional Ster-O-Zone system that will be validated in plant by PHARMACIA.

“Ozone is the most proficient antimicrobial oxidizing agent known,” said Dr. Durand Smith, President and Director of R&D, Cyclopss. “It’s capable of killing pathogens, such as EColi, 3,125 times faster than chlorine technology and because of its unique method of kill, no bacteria, virus or spore is able to build immunity or resistance to it.”

Management stated that one of the primary interests driving the potential for use of ozone technology by the pharmaceutical manufacturing, and packaging industry, is the fact that it creates only oxygen as a by-product of its killing action, leaving no other residual chemicals behind to potentially interact or degrade the sometimes sensitive pharmaceutical products.